Successful ceftolozane/tazobactam treatment of chronic pulmonary infection with pan‐resistant Pseudomonas aeruginosa

References

1. Andrews J.M. ( 2001). Determination of minimum inhibitory concentrations. J Antimicrob Chemother 48: (Suppl. 1) 5–16 [CrossRef]
   [Google Scholar]
2. Anonymous( 2014). ZERBAXA (ceftolozane/tazobactam) for injection, for intravenous use Initial U.S. Approval: 2014. Food and Drug Administration. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206829lbl.pdf
   [Google Scholar]
3. Ashish A., Paterson S., Mowat E., Fothergill J.L., Walshaw M.J., Winstanley C. ( 2013). Extensive diversification is a common feature of Pseudomonas aeruginosa populations during respiratory infections in cystic fibrosis. J Cyst Fibros 12:790–793 [CrossRef]
   [Google Scholar]
4. Boucher H.W., Talbot G.H., Benjamin D.K., Bradley J., Guidos R.J., Jones R.N., Murray B.E., Bonomo R.A., Gilbert D. the Infectious Diseases Society of America( 2013). 10×'20 Progress – development of new drugs active against Gram‐negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 56:1685–1694 [CrossRef]
   [Google Scholar]
5. British Society for Antimicrobial Chemotherapy( 2012). BSAC Methods for Antimicrobial Susceptibility Testing, version 12. http://bsac.org.uk/wp-content/uploads/2012/02/Version-12-Apr-2013_final1.pdf
6. Chandorkar G., Huntington J.A., Gotfried M.H., Rodvold K.A., Umeh O. ( 2012). Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects. J Antimicrob Chemother 67:2463–2469 [CrossRef]
   [Google Scholar]
7. European Committee on Antimicrobial Susceptibility Testing( 2014). Clinical breakpoints. http://www.eucast.org/clinical_breakpoints/.
8. Juan C., Zamorano L., Pérez J.L., Ge Y., Oliver A. Spanish Group for the Study of Pseudomonas & Spanish Network for Research in Infectious Diseases( 2010). Activity of a new antipseudomonal cephalosporin, CXA‐101 (FR264205), against carbapenem‐resistant and multidrug‐resistant Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother 54:846–851 [CrossRef]
   [Google Scholar]
9. Lepak A.J., Reda A., Marchillo K., Van Hecker J., Craig W.A., Andes D. ( 2014). Impact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target. Antimicrob Agents Chemother 58:6311–6314 [CrossRef]
   [Google Scholar]
10. Livermore D.M., Mushtaq S., Ge Y., Warner M. ( 2009). Activity of cephalosporin CXA‐101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates. Int J Antimicrob Agents 34:402–406 [CrossRef]
    [Google Scholar]
11. Shlaes D.M. ( 2013). New β‐lactam–β‐lactamase inhibitor combinations in clinical development. Ann N Y Acad Sci 1277:105–114 [CrossRef]
    [Google Scholar]
12. Turton J.F., Turton S.E., Yearwood L., Yarde S., Kaufmann M.E., Pitt T.L. ( 2010). Evaluation of a nine‐locus variable‐number tandem‐repeat scheme for typing of Pseudomonas aeruginosa . Clin Microbiol Infect 16:1111–1116 [CrossRef]
    [Google Scholar]
13. VanScoy B.D., Mendes R.E., Castanheira M., McCauley J., Bhavnani S.M., Jones R.N., Friedrich L.V., Steenbergen J.N., Ambrose P.G. ( 2014). Relationship between ceftolozane‐tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow‐fiber infection model. Antimicrob Agents Chemother 58:6024–6031 [CrossRef]
    [Google Scholar]